Rezultaty - Jonathan D. Cheng
- Rezultaty 1 - 20 Rezultaty od 28
- Idź do następnej strony
-
1
FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells od Hyung‐Ok Lee, Stefanie Mullins, Janusz Franco‐Barraza, Matthildi Valianou, Edna Cukierman, Jonathan D. Cheng
Wydane 2011Artigo -
2
-
3
Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival od Adam C. Berger, Jeffrey M. Farma, Walter J. Scott, Gary M. Freedman, Louis M. Weiner, Jonathan D. Cheng, Hao Wang, Melvyn Goldberg
Wydane 2005Revisão -
4
Pembrolizumab in Asia‐Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from <scp>KEYNOTE</scp>‐012 od Makoto Tahara, Kei Muro, Yasuhisa Hasegawa, Hyun Cheol Chung, Chia‐Chi Lin, Bhumsuk Keam, Kenichi Takahashi, Jonathan D. Cheng, Yung‐Jue Bang
Wydane 2017Artigo -
5
Photodynamic Molecular Beacon Triggered by Fibroblast Activation Protein on Cancer-Associated Fibroblasts for Diagnosis and Treatment of Epithelial Cancers od Pui‐Chi Lo, Juan Chen, Klara Stefflova, Michael S. Warren, Roya Navab, Bizhan Bandarchi, Stefanie Mullins, Ming‐Sound Tsao, Jonathan D. Cheng, Gang Zheng
Wydane 2008Artigo -
6
Long-Term Results of Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: A Phase II Trial of the Radiation Therapy Oncology Group (RTOG 99-... od Adam S. Garden, Jonathan Harris, Andy Trotti, Christopher U. Jones, Luis A. Carrascosa, Jonathan D. Cheng, Sharon Spencer, Arlene A. Forastiere, Randal S. Weber, K. Kian Ang
Wydane 2008Artigo -
7
Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14 od K. Kian Ang, Jonathan Harris, Adam S. Garden, Andy Trotti, Christopher U. Jones, Luis A. Carrascosa, Jonathan D. Cheng, Sharon Spencer, Arlene A. Forastiere, Randal S. Weber
Wydane 2005Artigo -
8
-
9
Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold od Koen Jansen, Leen Heirbaut, Jonathan D. Cheng, Jurgen Joossens, O.V. Ryabtsova, Paul Cos, Louis Maes, Anne‐Marie Lambeir, Ingrid De Meester, Koen Augustyns, Pieter Van der Veken
Wydane 2013Artigo -
10
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study od Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D. Cheng, Vassiliki Karantza, Laurence Buisseret
Wydane 2016Artigo -
11
Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation With Overdose Control in PNU-214936 od Jonathan D. Cheng, James S. Babb, Corey J. Langer, Steinar Aamdal, Francisco Robert, Lars Engelhardt, Olov Fernberg, Joan H. Schiller, G. Forsberg, R. Katherine Alpaugh, Louis M. Weiner, André Rogatko
Wydane 2004Artigo -
12
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study od Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason Chesney, Beatriz Castelo Fernández, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gümüşçü, Jonathan D. Cheng, Wendy Snyder, Lillian L. Siu
Wydane 2020Artigo -
13
Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer od Kalyani Narra, Stefanie Mullins, Hyung-Ok Lee, Brenda Strzemkowski-Brun, K. Magalong, Victoria J. Christiansen, Patrick A. McKee, Brian L. Egleston, Steven J. Cohen, Louis M. Weiner, Neal J. Meropol, Jonathan D. Cheng
Wydane 2007Artigo -
14
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esop... od André Konski, Tianyu Li, Michael Christensen, Jonathan D. Cheng, Jian Q. Yu, Kevin Crawford, Oleh Haluszka, Jeffrey L. Tokar, Walter J. Scott, Neal J. Meropol, Steven J. Cohen, Alan H. Maurer, Gary M. Freedman
Wydane 2012Artigo -
15
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer od Jennifer H. Yearley, Christopher J. Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan D. Cheng, Laura Q.M. Chow, Tanguy Y. Seiwert, Masahisa Handa, Joanne E. Tomassini, Terrill K. McClanahan
Wydane 2017Artigo -
16
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer od Janice M. Mehnert, Andréa Varga, Marcia S. Brose, Rahul Aggarwal, Chia‐Chi Lin, Amy Prawira, Filippo de Braud, Kenji Tamura, Toshihiko Doi, Sarina A. Piha‐Paul, Jill Gilbert, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Bhumsuk Keam
Wydane 2019Artigo -
17
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade od Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R. Kaufman, Andrew Albright, Jonathan D. Cheng, Shijun Kang, Veena Shankaran, Sarina A. Piha‐Paul, Jennifer H. Yearley, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan
Wydane 2017Artigo -
18
A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients od Robert A. Schnoll, Randi L. Rothman, Dustin B. Wielt, Caryn Lerman, Holly Pedri, Hao Wang, James S. Babb, Suzanne M. Miller, Benjamin Movasas, Eric J. Sherman, John A. Ridge, M. Unger, Corey J. Langer, Melvyn Goldberg, Walter J. Scott, Jonathan D. Cheng
Wydane 2005Artigo -
19
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study od Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis P. Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori J. Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert I. Haddad
Wydane 2017Artigo -
20
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer od Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim M. Hirshfield, Sherri Damare, Katherine Lane, Levi Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman, Siraj M. Ali, Jeffrey S. Ross, Dean C. Pavlick, Gyan Bhanot, Eileen White, Robert S. DiPaola, Ann Lovell, Jonathan D. Cheng, Shridar Ganesan
Wydane 2016Artigo
Narzędzie wyszukiwania:
Podobne hasła
Internal medicine
Medicine
Cancer
Oncology
Immunotherapy
Pembrolizumab
Head and neck cancer
Surgery
Biology
Head and neck squamous-cell carcinoma
Biochemistry
Cancer research
Gastroenterology
Chemistry
Phases of clinical research
Response Evaluation Criteria in Solid Tumors
Adverse effect
Chemotherapy
Fibroblast activation protein, alpha
Genetics
Radiation therapy
Clinical trial
Gene
Head and neck
Immune checkpoint
Progressive disease
Toxicity
Tumor microenvironment
Basal cell
Cohort